NASDAQ:SSKN - US86272A3059 - Common Stock
The current stock price of SSKN is 2.38 USD. In the past month the price increased by 22.05%. In the past year, price decreased by -31.31%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.07 | 230.89B | ||
ISRG | INTUITIVE SURGICAL INC | 58.79 | 169.67B | ||
BSX | BOSTON SCIENTIFIC CORP | 37.28 | 156.32B | ||
SYK | STRYKER CORP | 30.46 | 149.64B | ||
MDT | MEDTRONIC PLC | 16.78 | 119.05B | ||
BDX | BECTON DICKINSON AND CO | 13.52 | 55.31B | ||
IDXX | IDEXX LABORATORIES INC | 53.88 | 51.77B | ||
EW | EDWARDS LIFESCIENCES CORP | 31.65 | 47.75B | ||
RMD | RESMED INC | 28.74 | 40.19B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.82 | 33.66B | ||
DXCM | DEXCOM INC | 44.32 | 29.55B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 16.42 | 26.56B |
STRATA Skin Sciences, Inc. is a medical technology company in Dermatology and Plastic Surgery. The company is headquartered in Horsham, Pennsylvania and currently employs 106 full-time employees. The company went IPO on 2005-10-28. The firm is engaged in developing, commercializing and marketing products for the treatment of dermatologic conditions. The firm operates through two segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. The Company’s products include the XTRAC and Pharos excimer lasers and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its products also include the TheraClear Acne Therapy System utilized in the treatment of mild to moderate inflammatory, comedonal and pustular acne. The XTRAC and Pharos excimer laser technology emits highly concentrated ultraviolet (UV) light targeted primarily towards autoimmune dermatological skin disorders, such as psoriasis, vitiligo, atopic dermatitis, and eczema, among others. VTRAC is a UV light lamp system that works in much the same way as the XTRAC.
STRATA SKIN SCIENCES INC
5 Walnut Grove Drive, Suite 140
Horsham PENNSYLVANIA 19044 US
CEO: Robert J. Moccia
Employees: 106
Phone: 12156193200
The current stock price of SSKN is 2.38 USD. The price increased by 17.24% in the last trading session.
The exchange symbol of STRATA SKIN SCIENCES INC is SSKN and it is listed on the Nasdaq exchange.
SSKN stock is listed on the Nasdaq exchange.
8 analysts have analysed SSKN and the average price target is 8.16 USD. This implies a price increase of 242.86% is expected in the next year compared to the current price of 2.38. Check the STRATA SKIN SCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
STRATA SKIN SCIENCES INC (SSKN) has a market capitalization of 9.92M USD. This makes SSKN a Nano Cap stock.
STRATA SKIN SCIENCES INC (SSKN) currently has 106 employees.
STRATA SKIN SCIENCES INC (SSKN) has a resistance level at 2.39. Check the full technical report for a detailed analysis of SSKN support and resistance levels.
The Revenue of STRATA SKIN SCIENCES INC (SSKN) is expected to decline by -1.34% in the next year. Check the estimates tab for more information on the SSKN EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SSKN does not pay a dividend.
STRATA SKIN SCIENCES INC (SSKN) will report earnings on 2025-11-11, after the market close.
STRATA SKIN SCIENCES INC (SSKN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.84).
The outstanding short interest for STRATA SKIN SCIENCES INC (SSKN) is 1.68% of its float. Check the ownership tab for more information on the SSKN short interest.
ChartMill assigns a technical rating of 3 / 10 to SSKN. When comparing the yearly performance of all stocks, SSKN is a bad performer in the overall market: 88.06% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to SSKN. SSKN has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months SSKN reported a non-GAAP Earnings per Share(EPS) of -2.84. The EPS decreased by -16.87% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -26.71% | ||
ROE | -342.83% | ||
Debt/Equity | 5.71 |
8 analysts have analysed SSKN and the average price target is 8.16 USD. This implies a price increase of 242.86% is expected in the next year compared to the current price of 2.38.
For the next year, analysts expect an EPS growth of 37.76% and a revenue growth -1.34% for SSKN